肝癌切除术后栓塞化疗与LAK细胞／IL－2的作用

目的探讨肝癌切除术后进行栓塞化疗或（和）淋巴因子激活的杀伤细胞（ＬＡＫ）／白介素－２（ＩＬ－２）的远期疗效。方法回顾性分析肝癌切除术后３年以上患者１０４例，比较单纯切除（Ａ组）、切除加栓塞化疗（Ｂ组）和切除加栓塞化疗加ＬＡＫ细胞／ＩＬ－２（Ｃ组）的预后情况。结果３年生存率在Ａ、Ｂ、Ｃ组分别为３０％、５４．３％、５７．１％。根治性切除病例，Ａ、Ｂ、Ｃ组的３年复发率分别为７６．７％、４６．７％、４１．７％。单纯手术组的生存率显著低于其他两组，而根治性切除后的复发率则显著比另两组为高。结论肝癌切除联合栓塞化疗或（和）ＬＡＫ细胞／ＩＬ－２治疗有助于改善肝癌患者的预后。

EFFECT OF CHEMOEMBOLIZATION AND (OR) LAK CELL/IL-2 ON PRIMARY LIVER CANCER AFTER SURGICAL RESECTION

To observe the long-term effects of chemoembolization and LAK cell/IL-2 on primary liver carcinoma after surgical resection.METHODS 104 patients who had undergone hepatectomy were divided into 3 groups: 1. Hepatectomy only; 2. Chemoembolization after hepatectomy; 3. Chemoembolization and LAK/IL-2 treatment after hepatectomy.RESULTS For patients after radical resection, the 3-year recurrence rates were 76.7, 46.7, 41.7 per cent in groups 1,2 and 3 respectively. The 3-year survival rates were 30, 54.5 and 57.1 per cent in groups 1,2 and 3 respectively. Recurrence rates of group 2 or group 3 were significantly lower than those of group 1, while the survival rate in group 2 was lower than those of group 2 or group 3. CONCLUSIONS Chemoembolization and (or) LAK cell/IL-2 after surgical resection contribute to improvement of survival rates and to reduction of recurrence rates for patients with primary liver carcinoma.